Open Access

Potential use of glutathione as a treatment for Parkinson's disease

  • Authors:
    • Hai-Li Wang
    • Jun Zhang
    • Yu-Ping Li
    • Lun Dong
    • Ying-Zhu Chen
  • View Affiliations

  • Published online on: December 4, 2020     https://doi.org/10.3892/etm.2020.9557
  • Article Number: 125
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to assess the efficacy and safety of glutathione (GSH) for the treatment of Parkinson's disease (PD). The PubMed, Cochrane Library, OvidSP, Web of Science, China Science and Technology Journal Database, Chinese National Knowledge Infrastructure and China Wanfang Standards Database databases were systematically searched from the inception dates to October 1st, 2019, using the key words‘glutathione’ or ‘GSH’ and ‘Parkinson’ or ‘Parkinson's disease’ or ‘PD’. The quality of the included articles was assessed using the bias risk assessment tool of the Cochrane systematic evaluator manual (version 5.1.0). Pooled analysis of the relevant data was performed using RevMan 5.3 software and subgroup analysis was performed to determine the impact of the dosage (300 vs. 600 mg) on the outcome measures. A total of seven randomized controlled trials involving 450 participants were included in the meta‑analysis. The results of the present study indicated a statistically significant difference between the GSH and control groups, in terms of the Unified Parkinson's Disease Rating Scale (UPDRS) III [standard mean difference (SMD), ‑0.48; 95% CI, ‑(0.88‑0.08); P=0.02] and GSH peroxidase (SMD, 1.88; 95% CI, 0.52‑3.24; P=0.007). However, the differences in the UPDRS I (SMD, ‑0.04; 95% CI, ‑0.25‑0.16; P=0.70) and UPDRS II (SMD, 0.03; 95% CI, ‑0.17‑0.24; P=0.77) score and in side effects were not statistically significant between the groups. Subgroup analyses revealed that the dosage (300 vs. 600 mg) was an influencing factor for UPDRS III. The present study demonstrated that GSH may mildly improve motor scores in PD, but not at the expense of increased adverse events.
View Figures
View References

Related Articles

Journal Cover

February-2021
Volume 21 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang H, Zhang J, Li Y, Dong L and Chen Y: Potential use of glutathione as a treatment for Parkinson's disease. Exp Ther Med 21: 125, 2021.
APA
Wang, H., Zhang, J., Li, Y., Dong, L., & Chen, Y. (2021). Potential use of glutathione as a treatment for Parkinson's disease. Experimental and Therapeutic Medicine, 21, 125. https://doi.org/10.3892/etm.2020.9557
MLA
Wang, H., Zhang, J., Li, Y., Dong, L., Chen, Y."Potential use of glutathione as a treatment for Parkinson's disease". Experimental and Therapeutic Medicine 21.2 (2021): 125.
Chicago
Wang, H., Zhang, J., Li, Y., Dong, L., Chen, Y."Potential use of glutathione as a treatment for Parkinson's disease". Experimental and Therapeutic Medicine 21, no. 2 (2021): 125. https://doi.org/10.3892/etm.2020.9557